The Early Systemic Prophylaxis of Infection After Stroke Study
Open Access
- 1 July 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 36 (7), 1495-1500
- https://doi.org/10.1161/01.str.0000170644.15504.49
Abstract
Background and Purpose— Early infection after stroke is frequent but the clinical value of antibiotic prophylaxis in acute stroke has never been explored. Objective and Methods— The Early Systemic Prophylaxis of Infection After Stroke (ESPIAS) is a randomized, double-blind, placebo-controlled study of antibiotic prophylaxis in patients older than 18 years with nonseptic ischemic or hemorrhagic stroke enrolled within 24 hours from clinical onset. Interventions included intravenous levofloxacin (500 mg/100 mL/d, for 3 days) or placebo (0.9% physiological serum) in addition to optimal care. A sample size of 240 patients was calculated to identify a 15% absolute risk reduction of the primary outcome measure, which was the incidence of infection at day 7 after stroke. Secondary outcome measures were neurological outcome and mortality at day 90. Results— Based on a preplanned futility analysis, the study was interrupted prematurely when 136 patients had been included. Levofloxacin and placebo patients had a cumulative rate of infection of 6% and 6% ( P =0.96) at day 1; 10% and 12% ( P =0.83) at day 2; 12% and 15% ( P =0.66) at day 3; 16% and 19% ( P =0.82) at day 7; and 30% and 33% ( P =0.70), at day 90. Using logistic regression, favorable outcome at day 90 was inversely associated with baseline National Institutes of Health Stroke Scale (OR, 0.72; 95% CI, 0.59 to 0.89; P =0.002) and allocation to levofloxacin (OR, 0.19; 95% CI, 0.04 to 0.87; P =0.03). Conclusions— Prophylactic administration of levofloxacin (500 mg/100 mL/day for 3 days) is not better than optimal care for the prevention of infections in patients with acute stroke.Keywords
This publication has 20 references indexed in Scilit:
- Risk of Myocardial Infarction and Stroke after Acute Infection or VaccinationNew England Journal of Medicine, 2004
- Systemic Inflammatory Response Depends on Initial Stroke Severity but Is Attenuated by Successful ThrombolysisStroke, 2004
- Preventive Antibacterial Treatment Improves the General Medical and Neurological Outcome in a Mouse Model of StrokeStroke, 2004
- Inflammation and Infections as Risk Factors for Ischemic StrokeStroke, 2003
- European Stroke Initiative Recommendations for Stroke Management – Update 2003Cerebrovascular Diseases, 2003
- Stroke-induced Immunodeficiency Promotes Spontaneous Bacterial Infections and Is Mediated by Sympathetic Activation Reversal by Poststroke T Helper Cell Type 1–like ImmunostimulationThe Journal of Experimental Medicine, 2003
- Guidelines for the Early Management of Patients With Ischemic StrokeStroke, 2003
- Complications following Acute Ischemic StrokeEuropean Neurology, 2002
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993
- Neurochemical Studies on Quinolone Antibiotics: Effects on Glutamate, GABA and Adenosine Systems in Mammalian CNSBasic & Clinical Pharmacology & Toxicology, 1989